Stocks · News reference

Moderna shares are trading lower. The company announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200 in patients with solid tumors.

Jul 16, 2026, 6:53 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 27, 2026, 8:20 PMChris Katje
Dolly Parton Life of Philanthropy May Have Kept Singer From Billionaire Status: ‘I Don’t Work for Money, Never Did’
Dolly Parton left a lasting legacy across music, TV, film and entertainment. The singer also leaves behind a lifetime of philanthropy.
Read original at benzinga
MRNA
BenzingaAug 27, 2026, 8:00 PMBenzinga Newsdesk
Moderna Says FDA Approved sBLAs For 2026-2027 Spikevax And mNEXSPIKE Formulas Targeting JN.1-Lineage XFG Subvariant; Says Vaccines Expected Available In Coming Days
Read original at benzinga
MRNA
BenzingaAug 27, 2026, 5:25 PMPiero Cingari
Nvidia's Best Day Since April 2025, Cybersecurity Stocks Go Vertical: Stock Market Today
Nvidia surged 9% and cybersecurity names exploded higher, yet 10 of 11 S&P 500 sectors fell as yields firmed before Jackson Hole.
Read original at benzinga
BTCUSD BUG BURL CELH CRM
BenzingaAug 27, 2026, 1:31 PMVandana Singh
Moderna Borrows $2 Billion To Expand Oncology Business
Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth and strategically manage debt.
Read original at benzinga
MRK MRNA